CFDE Data Portal | Search LOC122455342

	Label	Description
	LOC122455342 Gene (Entity type)	ENSG00000284526 - testis-specific serine/proline-rich protein
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182710 Drp1 TFAM overexpression 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 2 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC122455342

ENSG00000284526 - testis-specific serine/proline-rich protein

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE182710 Drp1 TFAM overexpression 1 v 2 human dn

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 2 v 6 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 4 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.